Health‐economic analysis of real‐time continuous glucose monitoring in people with Type 1 diabetes
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the clinical benefits and cost‐effectiveness of the sensor‐augmented pump compared with self–monitoring of plasma glucose plus continuous subcutaneous insulin infusion in people with Type 1 diabetes. Methods: The CORE Diabetes Model was used to simulate disease progression in a cohort of people with baseline characteristics taken from a published meta‐analysis. Direct and indirect costs for 2010–2011 were calculated from a societal payer perspective, with cost‐effectiveness calculated over the patient's lifetime. Discount rates of 3% per annum were applied to the costs and the clinical outcomes. Results: Use of the sensor‐augmented pump was associated with an increase in mean discounted, quality–adjusted life expectancy of 0.76 quality–adjusted life years compared with continuous subcutaneous insulin infusion (13.05 ± 0.12 quality–adjusted life years vs 12.29 ± 0.12 quality–adjusted life years, respectively). Undiscounted life expectancy increased by 1.03 years for the sensor‐augmented pump compared with continuous subcutaneous insulin infusion. In addition, the onset of complications was delayed (by a mean of 1.15 years) with use of the sensor‐augmented pump. This analysis resulted in an incremental cost–effectiveness ratio of 367,571 SEK per quality–adjusted life year gained with the sensor‐augmented pump. The additional treatment costs related to the use of the sensor‐augmented pump were partially offset by the savings attributable to the reduction in diabetes‐related complications and the lower frequency of self‐monitoring of plasma glucose. Conclusions: Analysis using the CORE Diabetes Model showed that improvements in glycaemic control associated with sensor‐augmented pump use led to a reduced incidence of diabetes‐related complications and a longer life expectancy. Use of the sensor‐augmented pump was associated with an incremental cost–effectiveness ratio of 367,571 SEK per quality–adjusted life year gained, which is likely to represent good value for money in the treatment of Type 1 diabetes in Sweden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global healthcare expenditure on diabetes for 2010 and 2030
Zhang, P., Zhang, X., Brown, J., Vistisen, D., Sicree, R., Shaw, J., & Nichols, G. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.01.026 · Cited by 1,145
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Deiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
The impact of non-severe hypoglycemic events on work productivity and diabetes management
Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.02.001 · Cited by 284
Garg, S. K., Voelmle, M. K., Beatson, C. R., Miller, H. A., Crew, L. B., Freson, B. J., & Hazenfield, R. M. (2011) · Diabetes Care · doi:10.2337/dc10-1852 · Cited by 85
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
“for the treatment of type 1 diabetes in the Swedish health care system (41) [C].”
Fantasia, K. L., Wirunsawanya, K., Lee, C., & Rizo, I. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821995810 · Cited by 62
Hirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
Mathieu, C., Ahmed, W., Gillard, P., Cohen, O., Vigersky, R., de Portu, S., & Ozdemir Saltik, A. Z. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0438 · Cited by 16
Metadata
- Authors
- Roze, S., Saunders, R., Brandt, A. ‐., de Portu, S., Papo, N. L., & Jendle, J.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2015-01-06
- Volume
- 32
- Issue
- 5
- Pages
- 618-626
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2080320583
- Cited by
- 40
- References
- 7
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health‐economic analysis of real‐time continuous glucose monitoring in people with Type 1 diabetes. https://app.cochat.ai/papers/10.1111/dme.12661
- The paper
- Roze, S., Saunders, R., Brandt, A. ‐., de Portu, S., Papo, N. L., & Jendle, J. (2015). Health‐economic analysis of real‐time continuous glucose monitoring in people with Type 1 diabetes. Diabetic Medicine. https://doi.org/10.1111/dme.12661
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.